These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23438956)

  • 1. Blood atherogenicity as a target for anti-atherosclerotic therapy.
    Sobenin IA; Chistiakov DA; Bobryshev YV; Orekhov AN
    Curr Pharm Des; 2013; 19(33):5954-62. PubMed ID: 23438956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orekhov's Method: Reassessment of In vitro Lipid Uptake Assays.
    Jargin SV
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):122-5. PubMed ID: 26149440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination.
    Orekhov AN; Tertov VV; Pokrovsky SN; Adamova IYu ; Martsenyuk ON; Lyakishev AA; Smirnov VN
    Circ Res; 1988 Mar; 62(3):421-9. PubMed ID: 3342473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-modified Low-Density Lipoprotein as Atherogenic Factor of Patients' Blood: Development of Therapeutic Approaches to Reduce Blood Atherogenicity.
    Nikiforov NG; Zakiev ER; Elizova NV; Sukhorukov VN; Orekhov AN
    Curr Pharm Des; 2017; 23(6):932-936. PubMed ID: 28120723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Atherogenesis in human - clinical aspects of circulating immune complexes].
    Babintseva YD; Sergeeva AM; Karagodin VP; Orekhov AN
    Klin Med (Mosk); 2016; 94(5):325-32. PubMed ID: 30289642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value.
    Sobenin IA; Salonen JT; Zhelankin AV; Melnichenko AA; Kaikkonen J; Bobryshev YV; Orekhov AN
    Biomed Res Int; 2014; 2014():205697. PubMed ID: 25054132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in modulating atherogenic lipoproteins.
    White CR; Goldberg DI; Anantharamaiah GM
    Curr Opin Lipidol; 2015 Oct; 26(5):369-75. PubMed ID: 26270809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis.
    Summerhill VI; Grechko AV; Yet SF; Sobenin IA; Orekhov AN
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Approaches to Anti-atherosclerotic Therapy: Cell-based Models and Herbal Preparations (Review of Our Own Data).
    Orekhov AN; Grechko AV; Romanenko EB; Zhang D; Chistiakov DA
    Curr Drug Discov Technol; 2020; 17(3):278-285. PubMed ID: 30621565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy.
    Myasoedova VA; Ivashinnikova GA; Sobenin IA; Ivanova EA; Orekhov AN
    Curr Pharm Des; 2017; 23(8):1195-1206. PubMed ID: 28042768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies against low-density lipoprotein and atherogenic potential of blood.
    Kacharava AG; Tertov VV; Orekhov AN
    Ann Med; 1993 Dec; 25(6):551-5. PubMed ID: 8292305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Lipoproteins on Atherobiology: Emerging Insights.
    Feng M; Rached F; Kontush A; Chapman MJ
    Cardiol Clin; 2018 May; 36(2):193-201. PubMed ID: 29609748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atherogenic modification of low-density lipoproteins].
    Sukhorukov VN; Karagodin VP; Orekhov AN
    Biomed Khim; 2016 May; 62(4):391-402. PubMed ID: 27562992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for the Use of Sialidase Inhibitors in Anti-atherosclerotic Therapy.
    Sobenin IA; Markin AM; Glanz VY; Markina YV; Wu WK; Myasoedova VA; Orekhov AN
    Curr Med Chem; 2021 May; 28(12):2438-2450. PubMed ID: 32867633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification.
    Tertov VV; Kaplun VV; Sobenin IA; Orekhov AN
    Atherosclerosis; 1998 May; 138(1):183-95. PubMed ID: 9678784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
    Dallinga-Thie GM; Kroon J; Borén J; Chapman MJ
    Curr Cardiol Rep; 2016 Jul; 18(7):67. PubMed ID: 27216847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture.
    Tertov VV; Orekhov AN; Sayadyan KS; Serebrennikov SG; Kacharava AG; Lyakishev AA; Smirnov VN
    Atherosclerosis; 1990 Apr; 81(3):183-9. PubMed ID: 2350370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to reduction of blood atherogenicity.
    Orekhov AN; Melnichenko AA; Sobenin IA
    Oxid Med Cell Longev; 2014; 2014():738679. PubMed ID: 25101152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the pathogenesis of atherosclerosis.
    Wissler RW
    Am J Med; 1991 Jul; 91(1B):3S-9S. PubMed ID: 1867233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.